



No. 81/2021

TO UEFA MEMBER ASSOCIATIONS

For the attention of  
the President and the General Secretary

Your reference	Your correspondence of	Our reference RLE/VOU	Date 6 December 2021
----------------	------------------------	--------------------------	-------------------------

## 2022 WADA Prohibited List

Dear Sir or Madam,

In accordance with article 4.1 of the UEFA Anti-Doping Regulations, edition 2021, the [2022 WADA Prohibited List](#) will apply to all UEFA competitions from 1 January 2022.

For this purpose, we enclose the new list of prohibited substances, as well as the WADA Summary of Major Modifications and Explanatory Notes, which highlights the changes compared with the 2021 List. The List and the summary are also available on the WADA website ([www.wada-ama.org](http://www.wada-ama.org)).

Due to the nature of the changes – in particular, with respect to glucocorticoids and salbutamol – all players who currently use, or may need to use, these substances are strongly encouraged to seek specialist advice to determine whether they are or could be affected by the changes

### Main amendments to the 2022 List

As outlined in the 2022 Summary of Major Modifications and Explanatory Notes, the Major Modifications for 2022 include the following:

#### **S9. Glucocorticoids**

All injectable routes of administration will now be prohibited for glucocorticoids during the in-competition period. Examples of injectable routes of administration include: intravenous, intramuscular, periarticular, intra-articular, peritendinous, intratendinous, epidural, intrathecal, intrabursal, intralesional (e.g. intrakeloid), intradermal, and subcutaneous.

For clarification: oral administration of glucocorticoids, which remains prohibited in-competition, includes oromucosal, buccal, gingival and sublingual routes.

---

Other routes of administration (including inhaled and topical: dental-intracanal, dermal, intranasal, ophthalmological and perianal) are not prohibited when used within the manufacturer's licensed doses and therapeutic indications.

It is strongly recommended that athletes become familiar with and follow the minimum washout periods, expressed from the time of administration to the start of the in-competition period. These washout periods, which are highlighted in the [Summary of Major Modifications and Explanatory Notes](#), are based on the use of these medications according to the maximum manufacturer's licensed doses.

If there is a legitimate medical need for the use of a glucocorticoid, the player may apply for a Therapeutic Use Exemption (TUE). In case of an Adverse Analytical Finding in-competition, the player may apply for a retroactive TUE as provided for in the applicable rules.

For further information regarding the amendments to the rules on Glucocorticoids, please see the enclosed document '[Glucocorticoids and Therapeutic Use Exemptions](#)'.

### **S3. Beta-2 Agonists – Dosage of Salbutamol**

Regarding salbutamol, the daily dosing time intervals are modified to 600 micrograms over eight hours starting from the time any dose is taken (previously 800 micrograms over 12 hours). This is to reduce the risk of any potential AAF arising after high doses are taken at once. The total permitted daily dose remains at 1,600 micrograms over 24 hours. A TUE should be sought for doses in excess of these limits.

### **S0. Non-approved Substances**

For the first time, a substance has been included by name as an example in section S0 (Non-approved Substances) of the List. This substance, BPC-157, is an experimental peptide sold as a supplement, and it has been included in the 2022 List following a recent re-evaluation of its status.

For further information regarding WADA's approach to the routes of administration of glucocorticoids, the washout periods and the permitted dosage of salbutamol, please refer to the Summary of Major Modifications and Explanatory Note.

### **Therapeutic Use Exemptions (TUEs)**

All TUE applications are processed by UEFA in accordance with the 2021 WADA International Standard for Therapeutic Use Exemptions (ISTUE). Your team doctors are strongly advised to carefully read the enclosed, 'UEFA Guide to the WADA Prohibited List and TUEs', for more detailed information regarding TUEs.

UEFA's rules and procedures governing TUEs are harmonised with those of FIFA. Players who are participating in UEFA competitions or in senior international (national A team) friendly matches and need to use a prohibited substance or prohibited method for therapeutic purposes must request prior authorisation from UEFA by means of a UEFA TUE application form (enclosed).

---

The TUE application form must be completed and signed by the player and their treating physician, and then sent with a complete file of medical evidence to the UEFA anti-doping unit ([antidoping@uefa.ch](mailto:antidoping@uefa.ch)). In order to provide additional security, please encrypt the documents with a password and send the password in a separate email. Forms must be sent to UEFA only and not to NADOs. Except in cases of medical emergency, doctors must not administer a prohibited substance or prohibited method before a TUE has been granted by UEFA.

WADA publishes checklists on the requirements for TUE applications for many common medical conditions. Doctors must ensure that all the requirements are met before applying to UEFA for a TUE otherwise applications will be sent back to the applicant with a request for further information and the process for granting a TUE will be delayed. The guidance documents can be downloaded from the WADA website: <https://www.wada-ama.org/en/what-we-do/science-medical/therapeutic-use-exemptions/>

TUEs granted by FIFA are automatically valid for UEFA competitions. However, TUEs granted by NADOs are not valid for UEFA competitions unless they have been recognised by UEFA. In case of a TUE recognition request, the UEFA anti-doping and medical unit must be provided with a copy of the original application form and all medical information that was submitted to the authorising body (both translated into one of UEFA's official languages, if necessary) and any other specific document that may be requested by UEFA.

Players participating in youth-level international friendly matches (i.e. any national youth team up to and including Under-21s) must apply to their NADO for a TUE, and not to UEFA.

Please forward this circular, the UEFA Anti-Doping Regulations, 2021 edition, and the 2022 WADA Prohibited List immediately to your team doctors, who must in turn inform their players. The Prohibited List, the Guide to the WADA Prohibited List and TUEs and all other enclosed documents are also available on the dedicated anti-doping section of the UEFA website at:

<https://www.uefa.com/insideuefa/protecting-the-game/anti-doping/>

Should you have any queries or require additional information, please contact Rebecca Lee at [antidoping@uefa.ch](mailto:antidoping@uefa.ch)

Yours faithfully,

**U E F A**



Theodore Theodoridis  
General Secretary

---

## Enclosures

- [UEFA Anti-Doping Regulations, edition 2021](#)
- [2022 WADA Prohibited List](#)
- [WADA Summary of major modifications and explanatory notes](#)
- [Glucocorticoids and Therapeutic Use Exemptions](#)
- UEFA Guide to the WADA Prohibited List and TUEs
- UEFA TUE application form

## cc (with enclosures)

- UEFA Executive Committee
- UEFA Medical Committee
- UEFA TUE Committee
- European members of the FIFA Council
- FIFA, Zurich
- European national anti-doping organisations